Document:

Exhibit 10.1

Exhibit 10.1

FIRST AMENDMENT

TO

DEVELOPMENT/MASTER AGREEMENT

This First Amendment to Development/Master Agreement (the “Amendment”) is made this 22nd day
of April, 2010 (the “Effective Date”), by and between PositiveID Corporation, a Delaware
corporation formerly known as VeriChip Corporation (the “Company”), and Receptors, LLC, a Minnesota
limited liability company (“Receptors”). The Company and Receptors shall be referred to
individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, the Parties entered into that certain Development/Master Agreement, dated September
21, 2009 (the “Agreement”), and the Parties desire to enter into this Amendment to modify certain
terms of the Agreement.

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

1. Definitions. All capitalized terms used herein, except as modified or defined in
this Amendment, shall have the meaning given to such terms in the Agreement.

2. Amendment.

	 	a.	 	Exhibit B. Exhibit B to the Agreement shall be deleted and
replaced by the Exhibit B attached to this Amendment.

	 	b.	 	Exhibit D. The language set forth in the section entitled
“Phase II” of Exhibit D to the Agreement shall be deleted and replaced by the
following: “Phase II — The Company shall make a cash payment to Receptors of
$160,000, of which $60,000 shall be paid on April 23, 2010, $50,000 shall be paid
on July 1, 2010, and $50,000 shall be paid on October 1, 2010. In addition, the
Company shall issue to Receptors 240,000 shares of restricted Company common stock,
pursuant to the terms and conditions set forth in that certain Restricted Stock
Agreement, attached hereto as Attachment One, which Restricted Stock
Agreement shall be executed by the Parties on the Effective Date as a condition to
the issuance of the 240,000 shares of restricted Company common stock.”

3. No Implied Modifications; Inconsistencies. Except as expressly modified hereby, all
terms and provisions of the Agreement shall remain unchanged and in full force and effect. In the
event of an inconsistency between the terms of this Amendment and the terms of the Agreement, the
terms hereof shall control.

4. Counterparts. This Amendment may be executed in any number of counterparts, and all
such counterparts shall together constitute but one instrument. Facsimile and portable document
format signatures shall have the same force and effect as if such electronic signature pages were
an original thereof.

(Remainder of page intentionally left blank; signature page follows)

 

 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first
written above.

	 	 	 	 	 
	 	POSITIVEID CORPORATION

 	 
	 	By:  	/s/ William J. Caragol
 	 
	 	 	Name:  	William J. Caragol 	 
	 	 	Title:  	President and Chief Financial Officer 	 
	 
	 	RECEPTORS, LLC

 	 
	 	By:  	      /s/ Robert E. Carlson
 	 
	 	 	Name:  	Robert E. Carlson 	 
	 	 	Title:  	President 	 

 

 

 

EXHIBIT B

PROGRAM TITLE:

Development of a Point-of-Care and Clinical Laboratory Multiplexed Sensing System for the
Detection and Sub-type, including Specifically H1N1, Identification of the Influenza Virus.

PHASE II. PROTOTYPE DEVELOPMENT

SUMMARY DESCRIPTION:

Receptors will use its best efforts to develop of a prototype sensing system built on the
proof-of-principle from Phase I that will sub-type identify the influenza virus, especially H1N1,
in a nasal swab or nasal wash sample.

DELIVERABLE:

LAB-SCALE PROTOTYPE with report, device and demonstration.

PHASE II PROJECT PLAN:

1. DEVELOPMENT AND APPLICATION OF HTS SYSTEM (2 months)

	 	•	 	Development of magnetic bead, dendrimer, virus system in 384-well format for
high-thoughput selection of bead / dendrimer pairs.
	 
	 	•	 	Application to HTS to define critical variable parameters.

2. DEVELOPMENT OF DATA GRID TO EVALUATE THE KEY VARIABLES OF CARA, DENDRIMER, VIRUS SUB-TYPE AND
MATRIX (4 months)

	 	•	 	Application of the HTS to develop the single and multiplexed data.
	 
	 	•	 	Database evaluation of CARA and peptide-dendrimer competitor pairs for single and
multiplexed sub-type detection.
	 
	 	•	 	Selection of candidate single and multiplexed CARA and competitor pairs optimized with
respect to the virus sub-type and matrix variables.

3. PROOF-OF-CONCEPT DEMONSTRATION OF THE MULTIPLEXED, SUB-TYPE IDENTIFICATION DEVICE (2 months)

	 	•	 	Candidate to lead selection and optimization.
	 
	 	•	 	Multiplexed lead integration and point-of-care protocol in matrix (2 months)

4. LAB-SCALE PROTOTYPE (2 months)

	 	•	 	Prototype demonstration.
	 
	 	•	 	Lab-scale SOP’s

PHASE II TIMELINE: March 1, 2010 — December 31, 2010 (10 months)

	 	 	 
	1. DEVELOPMENT HTS SYSTEM (2 months)

	 	MAR-APR
	2. DEVELOPMENT OF DATA GRID (4 months)

	 	MAY-AUG
	3. PROOF-OF-CONCEPT DEMONSTRATION (2 months)

	 	SEP-OCT
	4. LAB-SCALE PROTOTYPE (2 months)

	 	NOV-DEC

 

1

 

ATTACHMENT ONE

RESTRICTED STOCK AGREEMENT

This RESTRICTED STOCK AGREEMENT (the “Agreement”) is made as of April 22, 2010 (the “Effective
Date”) between PositiveID Corporation, a Delaware corporation (the “Company”) and Receptors LLC, a
Minnesota limited liability company (“Receptors”).

Background Information

A. The parties to this Agreement are parties to a Development/Master Agreement, dated
September 21, 2009, by and between the Company and Receptors (the “Master Agreement”).

B. The parties to this Agreement have decided to execute an amendment to the Master Agreement,
dated as of even date herewith (the “Amendment”), pursuant to which the Company will issue
restricted shares of Company common stock, par value $0.01 per share, to Receptors.

C. Receptors desires to accept the Restricted Stock (as such term is defined below) pursuant
to the Amendment and agrees to be bound by the terms and conditions of this Agreement.

Agreement

1. Restricted Stock. As partial consideration for entering into the Amendment and
subject to the terms and conditions provided in this Agreement, the Company hereby issues to
Receptors 240,000 shares of Company common stock (the “Restricted Stock”) as of the Effective Date.
Such shares are fully paid and non-assessable. The extent to which Receptors’ right to transfer,
pledge or hypothecate the Restricted Stock becomes vested shall be determined in accordance with
the provisions of Section 2 of this Agreement.

2. Vesting. Receptors’ right to transfer, pledge or hypothecate the Restricted Stock
shall be determined in accordance with this Section 2. Receptors’ right to transfer, pledge or
hypothecate the Restricted Stock shall become fully vested and shall cease being restricted as
follows: (i) 80,000 shares shall vest on the Effective Date; (ii) 80,000 shares shall vest on June
30, 2010; and (iii) 80,000 shares shall vest on the earlier of (a) December 31, 2010 or (b)
completion and delivery to the Company of a prototype report, device and demonstration as provided
in Exhibit B, Phase II, to the Master Agreement, as amended.

3. Restrictions on Transfer; Legending of Shares. Until such time as any share of
Restricted Stock becomes vested pursuant to Section 2 of this Agreement, Receptors shall not have
the right to make or permit to occur any transfer, pledge or hypothecation of all or any portion of
the Restricted Stock, whether outright or as security, with or without consideration, voluntary or
involuntary. Any transfer, pledge or hypothecation not made in accordance with this Agreement shall
be deemed null and void. The certificate evidencing the Restricted Stock shall contain a legend in
substantially the following form:

“The shares evidenced by this certificate are subject to restrictions on
transfer set forth in the Restricted Stock Agreement, dated April 22, 2010,
between PositiveID Corporation (the “Company”) and Receptors, LLC, a copy of
which may be obtained from the Company at its principal executive offices.”

“The shares of common stock of the Company represented hereby have not been
registered under the Securities Act of 1933, as amended, or applicable state
securities laws and may not be transferred, pledged, hypothecated or otherwise
disposed of in the absence of an effective registration statement covering such
shares under that Act and any applicable state securities laws, unless, in the
opinion of counsel satisfactory to the Company, an exemption from registration
thereunder is available.”

 

1

 

4. Removal of Restriction. As each tranche of Restricted Stock vests pursuant to
paragraph 2 hereof, upon written notice to the Company by Receptors, the Company shall immediately
remove the restriction contained in the first paragraph of the legend referenced in paragraph 3
hereof.

5. Rights to Dividends and Voting Rights. During the period that the Restricted Stock
has not vested, subject to this Section 5, Receptors shall be entitled to all rights applicable to
shares of common stock of the Company so held, including the right to vote and receive dividends,
but provided, however, in the event of (i) any change in the common stock of the Company by reason
of any stock dividend, spin-off, split-up, spin-out, recapitalization, merger, consolidation,
reorganization, combination or exchange of shares or (ii) any distribution of common stock or other
securities of the Company in respect of such shares of common stock, Receptors agrees that any
certificate representing shares of such additional common stock or other securities of the Company
issued as a result of any of the foregoing shall be delivered to the Company and shall be subject
to all of the provisions of this Agreement as if initially received hereunder.

6. Governing Laws. This Agreement shall be construed and enforced in accordance with
the laws of the State of Delaware, without regard to any applicable conflicts of law. By accepting
the Restricted Stock, Receptors irrevocably and unconditionally consents to submit to the exclusive
jurisdiction of the courts of the State of Florida or of the United States of America, in each case
located in Palm Beach County, Florida, for any litigation arising out of or relating to this
Agreement (and agrees not to commence any litigation relating thereto except in such courts).
Receptors also irrevocably and unconditionally waives any objection to the laying of venue of any
litigation arising out of or related to this Agreement in the courts of the State of Florida or of
the United States of America, in each case located in Palm Beach County, Florida, and hereby
further irrevocably and unconditionally waives and agrees not to plead or claim in any such court
that any such litigation brought in any such court has been brought in an inconvenient forum.

7. Successors. This Agreement shall inure to the benefit of, and be binding upon, the
Company and Receptors and their legal representatives, successors and permitted assigns.

8. Severability. In the event that any one or more of the provisions or portion
thereof contained in this Agreement shall for any reason be held to be invalid, illegal or
unenforceable in any respect, the same shall not invalidate or otherwise affect any other
provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal or
unenforceable provision or portion thereof had never been contained herein.

9. Piggyback Registration. If at any time the Company proposes to register shares of its
common stock under the Securities Act of 1933, as amended (the “Securities Act”), in connection
with the public offering of such shares for cash (a “Proposed Registration”) other than a
registration statement on Form S-8 or Form S-4 or any successor or other forms promulgated for
similar purposes, the Company shall, at such time, promptly give Receptors written notice of such
Proposed Registration. Receptors shall have ten (10) days from its receipt of such notice to
deliver to the Company a written request specifying the amount of Restricted Stock that Receptors
intends to sell and Receptors’ intended method of distribution. Upon receipt of such request, the
Company shall use its commercially reasonable efforts to cause all Restricted Stock that Receptors
has been requested to register to be registered under the Securities Act to the extent necessary to
permit their sale or other disposition in accordance with the intended methods of distribution
specified in Receptors’ request; provided, however, that the Company shall have the right to
postpone or withdraw any registration effected pursuant to this Section 9 without obligation to
Receptors. If, in connection with any underwritten public offering for the account of the Company
or for stockholders of the Company that have contractual rights to require the Company to register
shares of common stock, the managing underwriter(s) thereof shall impose a limitation on the number
of shares of common stock which may be included in a registration statement because, in the judgment of such
underwriter(s), marketing or other factors dictate such limitation is necessary to facilitate such
offering, then the Company shall be obligated to include in the registration statement only such
limited portion of the Restricted Stock with respect to which Receptors has requested inclusion
hereunder as such underwriter(s) shall permit; provided, however, shares that are
eligible to be sold pursuant to Rule 144 (or any similar provision then in force) without
restriction under the Securities Act shall not be subject to the registration requirements of this
Section 9.

 

2

 

10. Notices. All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when
sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on
the next business day; (c) three (3) business days after having been sent by registered or
certified mail, return receipt requested, postage prepaid; or (d) one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt. All communications shall be sent as follows:

If to the Company:

PositiveID Corporation

1690 South Congress Avenue, Suite 200

Delray Beach, Florida 33445

Attn: William J. Caragol

If to Receptors:

Receptors LLC

Suite 501B/MD57

1107 Hazeltine Blvd.

Chaska, MN 55318

Attn: Robert E. Carlson, Ph.D

11. Headings. Section headings used herein are for convenience of reference only and
shall not be considered in construing this Agreement.

12. Additional Acknowledgements. By their signatures below (including electronic
signatures), Receptors and the Company agree that the Restricted Stock is granted under and
governed by the terms and conditions of this Agreement. Receptors has reviewed the terms of this
Agreement, has had an opportunity to obtain the advice of counsel prior to executing this Agreement
and fully understands all provisions of this Agreement.

13. Counterparts. This Agreement may be executed in any number of counterparts that
when taken together shall be considered one and the same agreement. Facsimile and portable
document format signatures shall have the same force and effect as if such electronic signature
pages were an original thereof.

(Remainder of page intentionally left blank; signature page follows)

 

3

 

IN WITNESS WHEREOF, the Company and Receptors have executed this Agreement as of the Effective
Date set forth above.

	 	 	 	 	 
	 	POSITIVEID CORPORATION

 	 
	 	By:  	/s/ William J. Caragol
 	 
	 	 	Name:  	William J. Caragol 	 
	 	 	Title:  	President 	 
	 
	 	RECEPTORS, LLC

 	 
	 	By:  	/s/ Robert E. Carlson
 	 
	 	 	Name:  	Robert E. Carlson 	 
	 	 	Title:  	Presidentexv10w1

Exhibit 10.1

James R. Tobin

President and Chief Executive Officer

One Boston Scientific Place

Natick, MA 01760-1537

508.650.8533 Tel

508.650.8657 Fax

www.bostonscientific.com

April 9, 2008

Mr. Timothy A. Pratt

2555 Grand Boulevard

Kansas City, Missouri 64108

Dear Tim:

On behalf of Boston Scientific Corporation and its Executive Committee, we are very pleased to
confirm our offer of employment to you. Your Boston Scientific title will be Executive Vice
President, Secretary and General Counsel. You will report to James R. Tobin, President and Chief
Executive Officer. As part of this offer, we are recommending your nomination (subject to Board
approval) as a member of Boston Scientific’s Executive Committee. We look forward to a productive
and successful working relationship and to your formal acceptance of
this offer of employment.

This
letter, the enclosed Employee Agreement and Code of Conduct summarize our understanding of the
terms of your employment and provide you the means to accept our offer as described.

SIGN-ON BONUS

Boston Scientific will provide you with a “one-time” sign-on bonus of $200,000 (gross amount), one
half to be paid within 30 days of your start date and the remaining half to be paid within 30 days
of your six-month anniversary of employment. You must be employed by Boston Scientific to receive
the sign-on bonus; should you leave Boston Scientific prior to the first anniversary of your start
date, you will be required to pay back the full amount(s) of the sign-on bonus you received.

COMPENSATION

Through annual and long-term programs, Boston Scientific’s compensation programs provide our
employees with significant compensation opportunities on a pay for performance basis. The objective
of these programs is to recognize and reward both individual and company performance.

Base
Salary: Base gross salary for this position will be $20,192.31 currently payable bi-weekly,
equivalent to $525,000 on an annualized basis. Your performance and compensation will generally be
reviewed on an annual basis. The Boston Scientific performance year currently runs from January 1
through December 31 of each year. If your date of employment is on or before November 1, you are
eligible to participate in the current year’s performance and compensation review based on your
manager’s

 

 

assessment of your performance. Any compensation change will be prorated based on your date of
employment. If your date of employment is after November 1, your first performance and compensation
review will occur in the following year.

Performance Incentive Plan: The Boston Scientific performance year currently runs from January 1
through December 31 of each year. The Performance Incentive Plan provides employees with the
opportunity for a variable financial incentive in recognition of individual and company performance
in a given year. You are eligible to participate in the annual Performance Incentive Plan beginning
this year and you will be eligible to receive a full-year’s bonus amount. Per the current plan,
your annual target incentive is 75% of base salary. Your actual award will be based on your
achievement of individual goals and the company’s achievement of corporate performance goals. Under
the current plan, you must be an active employee on December 31 of the then current year to be
eligible for payment. A copy of the 2008 Performance Incentive Plan will be provided to you.

Executive Allowance Plan: As a member of the Executive Committee, you will be eligible to
participate in the Boston Scientific Executive Allowance Plan. Under this Plan, you will receive
$25,000 annually in lieu of certain other perquisites. This payment is subject to applicable
withholdings and is typically payable in two equal installments of $12,500 each in the last pay
periods of the months of June and December. A copy of Boston Scientific’s Executive Allowance Plan
has already been provided to you.

Equity: As part of this offer of employment, the Compensation Committee of the Boston Scientific
Board of Directors (“Compensation Committee”) has approved a grant to you of an option to purchase
shares of Boston Scientific common stock having a value on your actual hire date (the date of
grant) of $1,000,000 and has also approved an award to you of Deferred Stock Units (“DSUs”) having
a value on your actual hire date (the date of grant) of $1,000,000. The stock option grant and DSU
award will be made pursuant to one of the Boston Scientific Long Term Incentive Plans. Our Long
Term Incentive Plans are designed to share the rewards of the business with individuals who most
significantly contribute to the achievement of the company’s strategic and operating goals.

Non-Qualified Stock Options: The option grant will provide you with the opportunity to purchase
shares of Boston Scientific common stock. The number of stock options will be calculated and the
exercise price per share will be set on your actual hire date, using the Fair Market Value of
Boston Scientific common stock on that date. The option grant will vest in four equal annual
installments beginning on the first anniversary of the date of grant and will expire on the
10th anniversary of the grant date. In all other respects the option grant will be
subject to the provisions of the applicable Long Term Incentive Plan and Non-Qualified Stock Option
Agreement. In accordance with the applicable Long Term Incentive Plan, any unvested stock options
will accelerate upon your Retirement, Disability, death or a Change in Control of Boston Scientific
(as those terms are defined in the applicable Long Term Incentive Plan) and remain exercisable
until the expiration of the stated term of the stock option.

2

 

DSU Award: The DSU award reflects Boston Scientific’s commitment to grant to you a number of shares
of Boston Scientific common stock (less applicable tax and other withholdings), to be issued to you
in five equal annual increments beginning on the first anniversary of the date of the grant. The DSU
Award will be granted on your actual hire date and the number of DSUs to be awarded will be
calculated using the Fair Market Value of Boston Scientific common stock on the date of grant. This
award is also subject to all provisions of the applicable Long Term Incentive Plan and Deferred
Stock Unit Agreement. In accordance with the applicable Long Term Incentive Plan, upon your
Retirement, Disability, death or a Change in Control of Boston Scientific (as those terms are
defined in the applicable Long Term Incentive Plan), we will issue to you or your beneficiary (as
the case may be), any shares of Boston Scientific stock to be awarded to you in accordance with
this letter that remain subject to eligibility conditions.

RELOCATION

To assist you with your move to the Boston area, Boston Scientific is pleased to provide you with
specific relocation benefits under the Tier V Executive Officer level of Boston Scientific’s
relocation program, with approval of any exceptions to be given by Lucia Quinn, Executive Vice
President, Human Resources. Diane Maroney, Boston Scientific’s Domestic Relocation Manager, will
contact you to discuss the relocation program in more detail. Please be aware that in connection
with the relocation assistance being offered, you will be required to sign an Agreement to
Reimburse form (a sample of which is enclosed) which, among other things, contains a requirement to
repay relocation costs if you leave the Company within a specified period of time for certain
reasons.

PLEASE NOTE: If Home Sale Assistance is an aspect of your relocation assistance, it is required
that your third-party relocation vendor be allowed to make the initial call to the realtor of your
choice. Therefore, please do not contact a realtor directly before coordination with Boston
Scientific, as to do so many impact your eligibility for relocation assistance.

Any relocation questions you may have should be directed to Diane Maroney, US Domestic Relocation
Manager, at 508-650-8483 or e-mail, maroneyd@bsci.com.

BENEFITS

Enclosed is descriptive literature regarding Boston Scientific’s current benefit programs. You
should review this information prior to your start date so you are prepared to enroll within your
first 31 days of employment. Please understand that the company reserves the right to unilaterally
amend or terminate any of these programs, or to require or change employee premium contributions
toward any benefits.

Executive Retirement Plan: As a member of the Executive Committee, if you “retire” from Boston
Scientific (as that term is defined in our Executive Retirement Plan), you may be eligible to
receive certain benefits provided in that Plan, including a lump sum payment equal to 2.5 months of
base salary times your years of service, subject to a

3

 

maximum benefit of 36 months. A copy of Boston Scientific’s Executive Retirement Plan has already
been provided to you.

Boston Scientific Retention and Indemnification Agreements: Boston Scientific also provides
retention and indemnification agreements to its key executives. In general, the retention agreement
entitles you as a member of our Executive Committee to a lump sum payment of three times your base
salary and assumed on-plan incentive bonus if either your employment is terminated (other than for
cause) or if your duties are diminished following a change in control of Boston Scientific.
Indemnification by Boston Scientific is also extended to key executives for liability arising in
the proper performance of one’s responsibilities as an executive officer of Boston Scientific. A
form of each agreement is enclosed for your information.

AUTHORIZATION TO WORK

Please note that this offer of employment is contingent upon your ability to provide, on your first
day of employment, a completed I-9 form and acceptable original documents that will establish your
identify and authorization to work in the U.S. in compliance with the Immigration Reform and
Control Act of 1986, a federal law. Please see the enclosed document “Orientation for New Hires”
for a list of acceptable identification documents. It is Boston Scientific’s practice to require
that these original identification documents be presented on the first day of employment, so please
remember to bring them.

BACKGROUND VERIFICATION

A background verification satisfactory to Boston Scientific has been completed as of your signature
date on this letter.

EMPLOYMENT AT WILL

Upon acceptance of this offer and your active start of employment, you will become an “at will”
employee of Boston Scientific. This means that you will be free to resign at any time. Likewise,
Boston Scientific will have the right to terminate your employment at any time with or without
reason or notice. Acceptance of this offer acknowledges your understanding and acceptance of the
“at will” nature of your employment.

(The remainder of this page is left intentionally blank.)

4

 

ACCEPTANCE

This offer letter is contingent upon the following:

	•	 	Successful completion of reference and background checks, as described in this letter;

	 
	•	 	A formal acceptance date no later than April 18,2008;

	 
	•	 	A start date of May 1, 2008; and

	 
	•	 	Your return of all completed, signed paperwork listed on the enclosed New Employee Checklist,
including but not limited to the Employee Agreement, so that Boston Scientific receives it four (4)
business days before your start date.

Please indicate your acceptance of this offer of employment and agreement with the terms described
in the enclosed documents by completing, signing and returning all enclosed paperwork at least four
(4) business days before your start date. The Code of Conduct, Benefits Literature and policy
documents should be retained by you for your records.

Tim, we believe that the opportunity here with Boston Scientific will be a mutually rewarding one
and we look forward to your acceptance of this offer.

Sincerely,

	 	 	 	 	 

	/s/ James R. Tobin
 

James R. Tobin

	 	/s/ Lucia Luce Quinn
 

Lucia Luce Quinn
	 	 
	President and Chief Executive Officer

	 	Executive Vice President,	 	 
	 

	 	Human Resources	 	 

	 	 	 	 	 

	Agreed to and Accepted by
	 	/s/ Timothy A. Pratt

 

Timothy A. Pratt
	 	Date: 4/10/08 

Enclosures:

Employee Agreement

Benefits Literature

Code of Conduct

New Employee Checklist/Forms/Equal Employment Policy Statement

Policy Against Harassment

Orientation for New Hires

Agreement to Reimburse

2008 Performance Incentive Plan

Retention Agreement

Indemnification Agreement

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]